Curanex provides operational update on regulatory milestones

Curanex (CURX) Pharmaceuticals announced the completion of a Good Manufacturing Practice-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N. This pilot marks a key manufacturing milestone in preparation for its planned Investigational New Drug submission for ulcerative colitis. Since completing its initial public offering in August 2025, Curanex has steadily advanced its lead program in strict alignment with U.S. Food and Drug Administration regulatory requirements, focusing on preclinical development and Chemistry, Manufacturing and Controls readiness. The Company continues to target submission of its first IND application for ulcerative colitis in the fourth quarter of 2026.